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With the goal of discovering new anti-infective agents active against microbial bioﬁlms, this investigation
focused on some natural pyrrolomycins, a family of halogenated pyrrole antibiotics. In this study the anti-
staphylococcal bioﬁlm activity of pyrrolomycins C, D, F1, F2a, F2b, F3 and of the synthesized related
compounds I, II, III were investigated. The susceptibility of six staphylococcal bioﬁlms was determined by
methyltiazotetrazolium staining. Most of the compounds were active at concentrations of 1.5 mg ml71 with
signiﬁcant inhibition percentages. A few of the compounds were active at the lowest screening concentration of
0.045 mg ml71. The population log reduction of activity against the two best bioﬁlm forming Staphylococcus
aureus strains as determined by viable plate counts is also reported. In order to adequately assess the utility of
these compounds, their toxicity against human cells was evaluated. It is concluded that pyrrolomycins and
synthetic derivatives are promising compounds for developing novel eﬀective chemical countermeasures against
staphylococcal bioﬁlms.
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Introduction
Staphylococcal bioﬁlms are a leading cause of device-
related infections of medical relevance. Staphylococcus
aureus is an important cause of metal-biomaterial,
bone joint, and soft tissue infections. Staphylococcus
epidermidis, on the other hand, is seen more often in
polymer associated infections (Go¨tz 2002). Together,
the Gram-positive pathogens S. aureus, S. epidermi-
dis, and Enterococcus faecalis represent more than
50% of the species isolated from patients with
medical device-associated infections (Donelli et al.
2007). The ability of S. aureus to form a bioﬁlm is
probably the virulence factor that contributes the
most to the development of the chronic and persistent
forms of infectious diseases like osteomyelitis (Brady
et al. 2008). A similar situation is seen in dairy cattle.
S. aureus is a major pathogen of mastitis, which is
one of the most common diseases in dairy cattle.
Although it has good in vitro antimicrobial suscept-
ibility, the therapy used to treat animals aﬀected
by mastitis is often disappointing and results in
recurrent clinical and chronic sub-clinical infections.
It has been suggested that these recurrent and chronic
staphylococcal infections can be attributed to
the growth of bacteria as bioﬁlms (Melchior et al.
2006).
Currently, no therapies that eﬀectively target
microbial bioﬁlms exist. This is in part because
bioﬁlms are intrinsically resistant to conventional
antibiotics (Gilbert et al. 2002). There is undoubtedly
an urgent need for new antibacterial drugs active
against not only planktonic bacteria but also bioﬁlms.
With this aim, the present study focused on the
halogenated pyrroles (Gribble 2003), pyrrolomycins
B-F, which are naturally produced by Actinosporan-
gium vitaminophylum. These compounds have been
described in the past as signiﬁcantly active agents
against Gram-positive bacteria (Ezaki 1983).
The authors recently reported anti Gram-positive
bacteria and the anti-staphylococci bioﬁlm activities of
3,4,5,30,50-pentabromo-2-(20-hydroxybenzoil) pyrrole
I (Schillaci et al. 2005), a synthetic compound related
to pyrrolomycin D. Furthermore, the pyrrolomycin
biosynthetic gene cluster has been recently cloned and
characterized (Zhang and Parry 2006).
This article aims to compare the anti-staphylococcal
bioﬁlm activity of some natural pyrrolomycins and
some related synthetic derivatives. To better under-
stand the utility of such compounds in the develop-
ment of novel anti-staphylococcal bioﬁlm agents, the
toxicity towards a human primary cell culture and the
selectivity indexes of these compounds were also
determined.
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Synthesis of pyrrolomycins and derivatives
Pyrrolomycins and derivatives were synthesized and
characterized as described (Raimondi et al. 2006). The
chemical structures of such molecules are reported in
Figure 1.
Bacterial strains
A group of bioﬁlm forming staphylococcal reference
strains, viz. S. aureus ATCC 25923, S. aureus ATCC
29213, S. epidermidis DSM 3269, and methicillin
resistant S. epidermidis RP62A was used. Two
staphylococcal isolates of veterinary interest were
also used: S. aureus 657 and S. aureus 702. Strain
657 was isolated from a milk sample from an
individual sheep aﬀected by mastitis. Strain 702 was
isolated from a bulk milk sample from a sheep ﬂock.
Determination of MICs
Minimum inhibitory concentrations (MICs) against
planktonic strains were determined as previously
described by a broth dilution micromethod (Schillaci
et al. 2005). Brieﬂy, a series of solutions with a range of
concentrations from 50 to 0.001 mg ml71 (obtained by
twofold serial dilution) was made in Mueller Hinton
broth (Merck) in a 96-well plate. To each well 10 ml of
a bacterial suspension, obtained from a 24 h culture,
containing *106 colony forming units (CFU) ml71
were added. The plate was incubated at 378C for 24 h.
After this time the MIC values were determined by a
microplate reader (ELX 800, Bio-Tek Instruments) as
the lowest concentration of compound whose optical
density (OD) at 570 nm, was comparable to the
negative control wells (broth only).
Molecular characterization
The two S. aureus strains of veterinary interest were
investigated for the presence of the intercellular
adhesion (ica) locus, which encodes polysaccharide
intercellular adhesin (PIA) and the bioﬁlm-associated
protein (BAP) gene, by site speciﬁc polymerase chain
reaction (PCR) with the primers used in a previous
study (Cucarella et al. 2004). The following PCR
conditions were adopted: 958C for 4 min, then 40
cycles (948C 6 30 s; 508C 6 30 s; 728C 6 50 s) at
728C for 5 min and then held at 48C.
The methicillin resistance gene (mecA) was also
detected by a multiplex PCR using the gene amp 9700
(Applied Biosystem) as described by Mehrotra et al.
(2000). DNA was extracted using QIAamp DNA mini
kit spin columns according to the manufacturer’s
instructions (Quiagen SpA, Milan, Italy).
Bioﬁlm forming evaluation
All the staphylococcal strains were tested for their
ability to form bioﬁlms. Brieﬂy, bacteria were grown
overnight in a shaking bath at 378C in Tryptic Soy
Broth (TSB, Sigma) containing 2% glucose and then
diluted 1:200 to a suspension with an OD of*0.040 at
570 nm. Polystyrene 24-well tissue culture plates were
ﬁlled with 1 ml of diluted suspension and incubated for
24 h at 378C. Then, the wells were washed three times
with 1 ml of sterile phosphate-buﬀered saline (PBS)
and stained with 1 ml of safranin (0.1% v/v) for 1 min.
The excess stain was removed by placing the plates
under running tap water. Plates were dried overnight in
an inverted position at 378C. Safranin-stained adher-
ent bacteria in each well were re-dissolved to homo-
geneity in 1 ml of 30% v/v glacial acetic acid, and the
OD was read at 492 nm. Each assay was performed in
triplicate and repeated at least twice.
Bioﬁlm susceptibility testing: the
methylthiazotetrazolium (MTT) method
Staphylococcal strains were grown in TSB containing
2% glucose, for 24 h at 378C in a shaking bath and
then diluted 1:200 in order to obtain a suspension
whose OD at 570 nm was *0.015. The diluted
suspension was added to the wells (100 ml per well)
of a polystyrene microtiter plate and incubated for
24 h at 378C. Then the wells were washed three times
with 200 ml of sterile PBS and ﬁnally air-dried in an
inverted position at 378C. Each of the wells was then
ﬁlled with 100 ml of Mueller-Hinton broth. With the
exception of the positive (growth) control wells, the
Mueller-Hinton broth was supplemented with concen-
trations, obtained by dilution, of 1.5 mg ml71 or
Figure 1. Chemical structures of pyrrolomycins and
derivatives.
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0.045 mg ml71 for each compound. Finally, the plates
were incubated at 378C for 24 h. Following this
incubation period, the medium was removed, the
plates were air-dried in an inverted position, and
each well was ﬁlled with 100 ml of PBS and 5 ml of a
5 mg ml71 MTT (methylthiazotetrazolium) solution
and incubated for 1 h at 378C. The insoluble purple
formazan obtained by cleavage of MTT made by the
dehydrogenase enzymes of living cells, was dissolved
by a mixture of isopropyl alcohol (9 ml), Triton X-100
(Sigma) (1 ml), and HCl 37% v/v (300 ml). The OD of
each well was read by a microplate reader (ELX 800,
Bio-Tek instruments) at 570 nm with background
subtraction at 630 nm. Comparing the average OD
of the growth control wells with that of sample wells
the following formula was used to calculate the
inhibition percentages for each concentration of the
compound:
ðOD growth controlOD sampleÞ=
OD growth control 100
Experiments were performed at least in triplicate.
Bioﬁlm susceptibility testing: viable plate counts
Staphylococcal strains were grown in TSB containing
2% glucose, incubated and diluted as in the MTT
method. The diluted suspension was added to the wells
(1000 ml per well) of a polystyrene microtiter 24-well
plate. Glass discs (12 mm diameter) were immersed in
each well and incubated for 24 h at 378C. Following
this incubation period the wells were washed three
times with 200 ml of sterile PBS and ﬁlled with 1000 ml
of Mueller-Hinton broth (except untreated growth
control wells) supplemented with concentrations of
0.045 mg ml71 of each compound. For comparative
and quality control purposes, other wells were
supplemented with rifampicin (Sigma) at a concentra-
tion of 0.045 mg ml71. Plates were incubated at 378C
for 24 h, the medium was removed, and the glass discs
were scraped three times. The inocula were put in test
tubes with 10 ml of NaCl (0.9% w/v solution) and
sonicated for 2 min. Six 10-fold dilutions were
prepared and 100 ml aliquots of each dilution were
plated onto Plate count agar (Biokar Diagnostics,
Beauvais, France). Plates were then incubated at 378C,
and CFU ml71 were counted after 18 h. Each assay
was performed in triplicate and repeated at least twice.
Mammalian cell cytotoxicity
A suspension (1 6 105 ml71) of a human primary cell
culture (Human Derm) was seeded into 96-well plates
and incubated for 72 h in a humidiﬁed incubator (95%
air, 5% CO2) until conﬂuence. At the time of the assay,
culture medium (MEM, Sigma-Aldrich, supplemented
with fetal calf serum and antibiotics) was replaced with
fresh RPMI medium (Sigma-Aldrich) without red
phenol. The test compounds were added at various
concentrations starting with a maximum concentration
of 75 mg ml71. The microtiter plate was incubated for
another 24 h and the toxicity was determined by MTT
assay (Mosmann 1983). The cytotoxicity was estimated
in terms of percent growth inhibition. IC50 values were
deﬁned as the test concentration at which the cell
proliferation was inhibited by 50% with respect to the
untreated growth control.
Results and discussion
Preliminary data were obtained by testing the anti-
bacterial activity of compounds against planktonic
staphylococcal strains. The results, expressed as MICs
and the geometric means of these MIC values are listed
in Table 1. The toxicity of these compounds against a
human normal cell culture (Human Derm) and the
selectivity index (ratio of cytotoxicity in terms of IC50
in mg ml71 to antibacterial activity expressed as the
geometric mean of the MICs) are also reported in
Table 1. All compounds, except pyrrolomycin C, were
Table 1. Antistaphylococcal activity of pyrrolomycins and related compounds against planktonic strains.
C D F1 F2a F2b F3 I II III
S. aureus ATCC 29213 3.2 0.001 0.001 0.001 0.03 0.01 0.01 0.2 0.1
S. aureus ATCC 25923 0.2 0.001 0.02 0.005 0.01 0.02 0.005 0.001 0.001
S. aureus 657 3.2 0.001 0.006 0.05 0.01 0.001 0.1 0.01 0.01
S. aureus 702 6.2 0.001 0.02 0.1 0.05 0.006 0.2 0.01 0.02
S. epidermidis DSM 3269 12.5 0.001 0.001 0.05 0.1 0.05 0.003 0.05 0.01
S. epidermidis RP62A 3.2 0.002 0.002 0.001 0.001 0.001 0.4 0.001 0.001




75 75 60 75 75 60 75 75 40
Selectivity index (IC50/MIC) 26.6 410000 410000 7500 4688 9600 2273 7500 5228
MIC expressed in mg ml71.
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eﬀective against all the tested strains with low MIC
values. In particular, pyrrolomycin D showed a
geometric mean of the MIC close to 0.001 mg ml71
for all staphylococcal strains. These results are in
accordance with previous reports that pyrrolomycin D
is one of the most active naturally produced organo-
halogens against Gram-positive pathogens (van Pee
and Ligon 2000). The data in Table 1 indicate that
most of the tested pyrrolomycins and related com-
pounds possessed a very interesting ‘‘safety margin’’ or
selectivity index as antibacterial agents. All of the
compounds, except pyrrolomycin C, showed a selec-
tivity index 41000 and in two cases (pyrrolomycins D
and F1) 410000.
Site-speciﬁc PCR were used to determine whether
or not the ica locus and BAP gene were present in the
ﬁeld isolates of S. aureus 657 and S. aureus 702. The
PCR results indicate that these strains contain both the
ica locus and the BAP gene. The ica locus can promote
bioﬁlm formation (Otto 2008) and the BAP gene,
which encodes a cell-wall-bound surface protein, plays
a role in ica-independent bioﬁlm mechanisms (O’Gara
2007) and infection of mammary glands (Cucarella
et al. 2004). The presence of the mecA gene was
detected only in strain 657.
Bioﬁlm formation was estimated for all strains used
in this study by staining adherent cells on polystirene
surfaces with safranin and reading the ODs. The tested
reference strains were observed to form more dense
bioﬁlms than the two staphylococcal isolates of
veterinary interest (Table 2).
The anti-bioﬁlm activity of pyrrolomycins and
derivatives against all staphylococcal strains was
evaluated using MTT for detecting live and adherent
bacteria (Walencka et al. 2007). Tables 3 and 4 show
the activities, in terms of percentage inhibition, at the
concentrations of 1.5 and 0.045 mg ml71. The com-
pounds, with the exception of pyrrolomycin C, were
active against all reference and ﬁeld isolate staphylo-
coccal bioﬁlms at the highest tested concentration of
1.5 mg ml71. The inhibition percentages were 460%
for all the compounds and in many cases 480%
(Table 3). To better understand the utility of such
Table 2. Bioﬁlm production in test staphylococcal strains.
OD at 492nm
S. aureus ATCC 29213 2.190 + 0.20
S. aureus ATCC 25923 1.956 + 0.17
S. aureus 657 0.646 + 0.019
S. aureus 702 0.732 + 0.021
S. epidermidis DSM 3269 3.380 + 0.085
S. epidermidis RP62A 3.010 + 0.35
Safranin method. Values are the average + SD of at least three
independent determinations.
Table 3. Anti-bioﬁlm activity of pyrrolomycins and related compounds.
C D F1 F2a F2b F3 I II III
S. aureus ATCC 29213 73.3 75.6 87 81 77 78.6 89 67.9 67.3
S. aureus ATCC 25923 62.8 70 68.3 75.3 75.8 76.5 68.5 84 84
S. aureus 657 78.5 75 85.3 84 80.5 85.6 85.3 69.5 81
S. aureus 702 63.5 79.5 84.3 82 79.3 84.3 85.6 74.5 71
S. epidermidis DSM 3269 NS 79.5 78.8 82.5 81 79.5 100 86.7 84.4
S. epidermidis RP62A 69.5 84.5 83 84.5 84.5 87.5 78 85 81
Mammalian cell cytotoxicity IC50 (mg ml
71) 75 75 60 75 75 60 75 75 40
Selectivity index (IC50/anti-bioﬁlm conc.) NT 50 40 50 50 40 50 50 26.6
MTT method. Screening at 1.5 mg ml71. Activity expressed as percentage inhibition. Values are the average of at least three independent
determinations. The variation coeﬃcient was 515%; NS, not signiﬁcant because below 15% inhibition; NT, not tested.
Table 4. Anti-bioﬁlm activity of pyrrolomycins and related compounds.
C D F1 F2a F2b F3 I II III
S. aureus ATCC 29213 26 28 39 69 35 63 58 63 51
S. aureus ATCC 25923 24 37 46 53 40 72 27 60 57
S. aureus 657 NS 74 62 59.3 59.6 72 48.5 68.3 76
S. aureus 702 NS 60 41 39 30 65 28 70 69
S. epidermidis DSM 3269 NS 63 54 52 62 64 49.4 71 71
S. epidermidis RP62A NS 25 38 41 25 73 26 56 65
Mammalian cell cytotoxicity IC50 (mg ml
71) 75 75 60 75 75 60 75 75 40
Selectivity index (IC50/anti-bioﬁlm conc.) NT NT NT NT NT 1333 NT 1666 889
MTT method. Screening at 0.045 mg ml71. Activity expressed as percentage inhibition. Values are the average of at least three independent
determinations. The variation coeﬃcient was 515%; NS, not signiﬁcant because below 15% oinhibition; NT, not tested.
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compounds as potential anti-staphylococcal bioﬁlm
agents, the selectivity index (ratio of IC50 to anti-
bioﬁlm concentration) for the 1.5 mg ml71 treatment
was also determined and reported in the same Table.
Due to the high concentration used, the selectivity
indexes as anti-bioﬁlm agents were very low (50 or
less).
Test compounds were also evaluated at a mini-
mum screening concentration of 0.045 mg ml71. In
this case, pyrrolomycin F3 and the synthetic deriva-
tives II and III were eﬀective as anti-bioﬁlm agents,
showing inhibition percentages 450% against all
tested strains. Signiﬁcant selectivity indexes for the
0.045 mg ml71 treatment were also found for these
compounds. These were 41000 for pyrrolomycin F3
and compound II, and close to 900 for compound III
(Table 4).
The eﬀectiveness of pyrrolomycins against the
two best S. aureus bioﬁlm formers at the lowest
screening concentration of 0.045 mg ml71 was also
evaluated in terms of log reductions based on viable
plate count. Their eﬀectiveness was compared to
rifampicin, which has been described as an excellent
agent alone or in combination with other antibiotics
in the treatment of staphylococcal bioﬁlms (Trampuz
and Zimmerli 2006). The CFU ml71 for adherent
cells grown on glass discs was assessed after scraping
and sonicating and is reported in Figures 2 and 3. At
0.045 mg ml71, rifampicin had weak activity against
S. aureus ATCC 25923 (0.97-log reduction). However,
stronger activity was observed in the presence of
pyrrolomycin F2b (1.22-log reduction) and pyrrolo-
mycin D (1.92-log reduction). No anti-bioﬁlm activity
was observed in the presence of rifampicin at 0.045 mg
ml71 against S. aureus ATCC 29213. In contrast,
pyrrolomycin F2a and synthetic compound I showed
a signiﬁcant log reduction (around 1.20 logs) against
this strain.
In conclusion, natural pyrrolomycins and synthetic
derivatives are promising compounds for developing
novel eﬀective chemical countermeasures against
staphylococcal bioﬁlms. Some compounds showed
anti-bioﬁlm properties at 0.045 mg ml71, a concentra-
tion that can be considered a good starting point for
novel potential anti-bioﬁlm agents. Moreover, con-
sidering the human cell cytotoxicity, their selectivity
indexes are very interesting, ie 41000. A selectivity
index value of4200 can be considered a good ‘‘safety
margin’’ to select a compound as a candidate for
potential therapeutic development as antimicrobial
agent (Suto et al. 1992). Nonetheless, further investiga-
tions are needed. The authors plan to evaluate and
compare the anti-bioﬁlm properties of each compound
using diﬀerent bioﬁlm growth models including animal
models to better understand and explain their potential
therapeutic use.
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